Cancer News and Research

Latest Cancer News and Research

UCLA Health System launches hand transplantation program

The UCLA Health System has launched the new UCLA Hand Transplantation Program, the first of its kind on the West Coast and only the fourth such center in the United States. The program will help those who have suffered the traumatic loss of a hand or forearm and allow them to regain function and improve their quality of life. Qualified candidates are now being sought for a clinical study of the procedure.

27 Jul 2010

CPC partners with CU School of Medicine on stem cell research

A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

26 Jul 2010

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.

26 Jul 2010

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

26 Jul 2010

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

Our system of long-term care does not provide adequate or coordinated human services and medical treatment for our growing aging population. … Thanks to a provision of the new health care law known as the Community Living Assistance Services and Supports program, tomorrow's continuum of care does not have to be so unforgiving. For the first time, a voluntary public insurance program will be available to help adults and families pay for long-term care services (Bruce Chernof, 7/23).

26 Jul 2010

Brainlab launches ExacTrac Infrared Monitoring device for patient positioning during radiation therapy

Brainlab announced the availability of ExacTrac® Infrared Monitoring, an add-on device to existing treatment machines for monitoring patient positioning during radiation therapy treatments, at the American Association of Physicists in Medicine (AAPM) Annual Meeting last week.

26 Jul 2010

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus standard-of-care.

26 Jul 2010

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc.. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a humanized antibody to hepatocyte growth factor (HGF).

26 Jul 2010

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

26 Jul 2010

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical Incorporated today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. The Vaxfectin® adjuvant substantially improved vaccine effectiveness. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection.

26 Jul 2010

Aptium Oncology to provide administrative services at new Beth Israel Comprehensive Cancer Center

Offering greater access to cancer care services for Manhattan West Side residents in New York, Beth Israel Medical Center has opened the Beth Israel Comprehensive Cancer Center - West Side Campus in the facility formerly known as St. Vincent's Comprehensive Cancer Center (SVCCC). The facility, which originally opened in 1996, was one of a few Saint Vincent's outpatient services units untouched and left open when the iconic hospital closed its doors on April 30, 2010. An official ribbon-cutting ceremony launched the center on Wednesday, July 14, 2010.

26 Jul 2010

Kindergarten puppet show reduces anxiety of kids with cancer

THE PUPPET SHOW IS PART OF THE BACK-TO-SCHOOL PROGRAM AT DANA-FARBER CANCER INSTITUTE IN BOSTON. IT'S DESIGNED TO REDUCE THE ANXIETY OF CHILDREN LIVING WITH CANCER. LISA SCHERBER (SHER-BURR) HEAD'S UP THE PROGRAM.

26 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

IDC secures $32 million in Series B financing

Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.

26 Jul 2010

Study compares current state of healthcare system in UK and proposed system in US

A comparison of the current state of the healthcare system in the UK and the new system proposed under legislation pushed through by Barack Obama's government, shows some surprising results. The review is published in the Journal of the Royal Society of Medicine (JRSM).

26 Jul 2010

Council seeks to limit medical resident working hours for improved patient care

As the Accreditation Council for Graduate Medical Education seeks to improve patient care by further limiting the hours worked by medical residents, the Journal of Surgical Research will published a new study online on Monday reporting that outcomes in two common surgeries - appendectomy and laparoscopic cholecystectomy - were similar among residents who had worked less than 16 hours and those who had worked more than 16 hours.

26 Jul 2010

School program to help children continue normal educational activities during treatment

Treatment for cancer and other catastrophic disease can last months or years and often makes it impossible for young patients to keep up with their local school curriculum. Teachers in the St. Jude School Program Presented by Target help patients continue their normal educational activities while away from their local schools. They are also part of the health care team that provides opportunities to continue normal educational activities through homebound or hospital-bound educational services. In addition, the team provides school re-entry services to ease the transition back to the community school.

26 Jul 2010

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

Asuragen, Inc. announced today the results from two collaborative studies, one with the University of California Davis M.I.N.D. Institute and another with Rush University Medical Center, that demonstrate comprehensive molecular profiling of the Fragile X Mental Retardation (FMR1) gene using advanced PCR-based methods.

26 Jul 2010

No such thing as “safe” cigarettes

In a new development a 12-member US panel is debating over the issue of menthol cigarettes being more addictive. If the results go against the cigarettes Australia too will have to ban the sale of such cigarettes. This would mean a significant loss to Alpine cigarettes and imported brands such as Kool, Virginia Slims and Salem.

26 Jul 2010

Obesity linked to rising womb cancer in women: Report

According to a new report from the Charity Cancer Research (CCR) in Britain, the number of women with womb cancer or uterine cancer is on the rise and obesity may be a clue to such rise.

26 Jul 2010

Cancer News and Research

Latest Cancer News and Research

UCLA Health System launches hand transplantation program

CPC partners with CU School of Medicine on stem cell research

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

Brainlab launches ExacTrac Infrared Monitoring device for patient positioning during radiation therapy

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Aptium Oncology to provide administrative services at new Beth Israel Comprehensive Cancer Center

Kindergarten puppet show reduces anxiety of kids with cancer

Axela acquires Xceed Molecular

IDC secures $32 million in Series B financing

Study compares current state of healthcare system in UK and proposed system in US

Council seeks to limit medical resident working hours for improved patient care

School program to help children continue normal educational activities during treatment

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

No such thing as “safe” cigarettes

Obesity linked to rising womb cancer in women: Report

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in